Cholesterol

Cholesterol

ollow">10.1016/S0092-8674(00)80213-5. 
  • ^ a b Tymoczko, John L.; Stryer Berg Tymoczko; Stryer, Lubert; Berg, Jeremy Mark (2002). Biochemistry. San Francisco: W.H. Freeman. pp. 726–727.  
  • ^ Weingärtner O, Pinsdorf T, Rogacev KS, Blömer L, Grenner Y, Gräber S, Ulrich C, Girndt M, Böhm M, Fliser D, Laufs U, Lütjohann D, Heine GH (2010). Federici, Massimo, ed. "The relationships of markers of cholesterol homeostasis with carotid intima-media thickness". PLoS ONE 5 (10): e13467.  
  • ^ Lewis GF, Rader DJ (June 2005). "New insights into the regulation of HDL metabolism and reverse cholesterol transport". Circ. Res. 96 (12): 1221–32.  
  • ^ Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA (January 1989). "High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies". Circulation 79 (1): 8–15.  
  • ^ Kandutsch AA, Chen HW, Heiniger HJ (August 1978). "Biological activity of some oxygenated sterols". Science 201 (4355): 498–501.  
  • ^ Russell DW (December 2000). "Oxysterol biosynthetic enzymes". Biochim. Biophys. Acta 1529 (1–3): 126–35.  
  • ^ Hanukoglu I, Jefcoate CR (1980). "Pregnenolone separation from cholesterol using Sephadex LH-20 mini-columns". Journal of Chromatography A 190 (1): 256–262.  
  • ^ Javitt NB (December 1994). "Bile acid synthesis from cholesterol: regulatory and auxiliary pathways". FASEB J. 8 (15): 1308–11.  
  • ^ Wolkoff AW, Cohen DE (February 2003). "Bile acid regulation of hepatic physiology: I. Hepatocyte transport of bile acids". Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2): G175–9.  
  • ^ Marschall HU, Einarsson C (June 2007). "Gallstone disease". J. Intern. Med. 261 (6): 529–42.  
  • ^ Gérard P, Lepercq P, Leclerc M, Gavini F, Raibaud P, Juste C (September 2007). "Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces". Appl. Environ. Microbiol. 73 (18): 5742–9.  
  • ^ Wipperman MF, Sampson NS, Thomas ST (2014). "Pathogen roid rage: Cholesterol utilization by Mycobacterium tuberculosis". Crit. Rev. Biochem. Mol. Biol. 49 (4): 269–93.  
  • ^ Thomas ST, Sampson NS (2013). "Mycobacterium tuberculosis utilizes a unique heterotetrameric structure for dehydrogenation of the cholesterol side chain". Biochemistry 52 (17): 2895–2904.  
  • ^ Wipperman MF, Yang M, Thomas ST, Sampson NS (2013). "Shrinking the FadE Proteome of Mycobacterium tuberculosis: Insights into Cholesterol Metabolism through Identification of an α2β2 Heterotetrameric Acyl Coenzyme A Dehydrogenase Family". J. Bacteriol. 195 (19): 4331–4341.  
  • ^ Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL (April 2008). "Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation". Diabetes Care 31 (4): 811–22.  
  • ^ Durrington P (August 2003). "Dyslipidaemia". Lancet 362 (9385): 717–31.  
  • ^ "Canadian scientists discover cause of high cholesterol". 
  • ^ a b Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R (December 2007). "Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths". Lancet 370 (9602): 1829–39.  
  • ^ "Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report" (PDF). National Institutes of Health. National Heart, Lung and Blood Institute. Retrieved 2008-10-27. 
  • ^
  • ^ "How Can I Lower High Cholesterol". American Heart Association. Retrieved 2011-04-03. 
  • ^ "Good Cholesterol Foods". Good Cholesterol Foods. Retrieved 2011-04-03. 
  • ^ National Institute for Health and Clinical Excellence. Clinical guideline 67: Lipid modification. London, 2008.
  • ^
  • ^ Nicholls SJ (August 2008). "Rosuvastatin and progression of atherosclerosis". Expert Rev Cardiovasc Ther 6 (7): 925–33.  
  • ^ "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial". Lancet 360 (9326): 7–22. July 2002.  
  • ^ Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (November 1995). "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group". N. Engl. J. Med. 333 (20): 1301–7.  
  • ^ Grundy SM (May 2007). "Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes". BMJ 334 (7601): 982–982.  
  • ^ Kendrick M (May 2007). "Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No". BMJ 334 (7601): 983–983.  
  • ^ JUPITER Study Group (2008). "Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein". N Engl J Med. 
  • ^ Mayberry JF, Atkinson M (2009). "The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials". BMJ 338: b2376.  
  • ^ , (January 1988). "Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel". Arch. Intern. Med. 148 (1): 36–69.  
  • ^ "Cholesterol". American Heart Association. 17 November 2008. Retrieved 2009-02-21. 
  • ^ "About cholesterol" – American Heart Association
  • ^ Warnick GR, Knopp RH, Fitzpatrick V, Branson L (January 1990). "Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints". Clin. Chem. 36 (1): 15–9.  
  • ^ Wang TY, Newby LK, Chen AY, Mulgund J, Roe MT, Sonel AF, Bhatt DL, DeLong ER, Ohman EM, Gibler WB, Peterson ED (September 2009). "Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome". Clin Cardiol 32 (9): E22–8.  
  • ^ Anderson KM, Castelli WP, Levy D (April 1987). "Cholesterol and mortality. 30 years of follow-up from the Framingham study". JAMA 257 (16): 2176–80.  
  • ^ Ulmer H, Kelleher C, Diem G, Concin H (2004). "Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality". J Women's Health (Larchmt) 13 (1): 41–53.  
  • ^ Daniel Steinberg (2007). The Cholesterol Wars: The Cholesterol Skeptics vs the Preponderance of Evidence. Boston: Academic Press.  
  • ^ Uffe Ravnskov (2000). The Cholesterol Myths : Exposing the Fallacy that Saturated Fat and Cholesterol Cause Heart Disease. New Trends Publishing, Incorporated.  
  • ^ Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E (2014). "Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic review and meta-analysis". Annals of internal medicine 160 (6): 398–406.  
  • ^ "How To Get Your Cholesterol Tested". American Heart Association. Retrieved 2013-07-10. 
  • ^ Stone NJ, Robinson J, Goff DC, Jr (2013). "Getting a grasp of the Guidelines". American College of Cardiology. Retrieved 2 April 2014. 
  • ^ "Implications of Recent Clinical Trials for the ATP III Guidelines". National Heart, Lungs and Blood Institute. Retrieved 2014-01-27. 
  • ^ Westover EJ, Covey DF, Brockman HL, Brown RE, Pike LJ (December 2003). "Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers". J. Biol. Chem. 278 (51): 51125–33.  
  • ^ Kristiana I, Luu W, Stevenson J, Cartland S, Jessup W, Belani JD, Rychnovsky SD, Brown AJ (September 2012). "Cholesterol through the looking glass: ability of its enantiomer also to elicit homeostatic responses". J. Biol. Chem. 287 (40): 33897–904.